OAF Inhibitors
OAF inhibitors encompass a diverse range of chemical compounds that exert their inhibitory effects through multiple mechanisms across various signaling pathways. The interruption of kinase activity forms a primary basis for OAF inhibition, as kinases play an integral role in the activation of OAF through phosphorylation. Compounds like staurosporine and Gö6983 target protein kinases, including those specifically involved in the phosphorylation of OAF, thereby preventing its activation. Other kinase inhibitors like PP2 focus on Src family kinases that might be implicated in upstream signaling processes essential for OAF function.
Additionally, the inhibition of key pathways like PI3K/Akt and MAPK/ERK by LY294002, wortmannin, PD98059, and U0126 also contribute significantly to the reduction of OAF activity. These pathways are crucial for multiple cellular processes, including those that might activate OAF. Compounds like rapamycin target mTOR within the PI3K/Akt pathway, which is a critical nodal point for protein synthesis and cell proliferation, affecting the cellular resources available for OAF function. Furthermore, inhibitors such as lapatinib and sorafenib act on tyrosine kinase domains and multiple kinases, respectively, to prevent the activation of downstream signaling events that would otherwise lead to OAF activation.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases, including Protein Kinase C (PKC). PKC is involved in the phosphorylation of OAF, which is necessary for OAF's stabilization and activation. By inhibiting PKC, staurosporine prevents the phosphorylation and subsequent activation of OAF. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a phosphoinositide 3-kinase (PI3K) inhibitor. PI3K is upstream of the Akt signaling pathway, which can lead to the activation of certain proteins, including OAF. Inhibition of PI3K by LY294002 can prevent the activation of Akt and consequently reduce OAF activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin specifically inhibits mTOR (mammalian target of rapamycin), which is part of the PI3K/Akt pathway. mTOR inhibition can lead to a reduction in protein synthesis and cell proliferation, which can indirectly decrease the activity of OAF by limiting the cellular resources necessary for its function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). JNK is implicated in the regulation of a variety of proteins via phosphorylation. Inhibition of JNK by SP600125 can lead to a decrease in the phosphorylation-dependent activation of OAF. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. The p38 MAP kinase pathway is involved in cellular responses to cytokines and stress, which can regulate the activity of OAF. By inhibiting p38 MAPK, SB203580 can suppress the activation of OAF that is dependent on this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that specifically blocks the MAPK/ERK pathway. This pathway is involved in the phosphorylation and activation of various proteins, potentially including OAF. Inhibition of MEK by PD98059 can lead to decreased activation of OAF through this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor that impedes the MAPK/ERK pathway. By blocking MEK, U0126 can inhibit the downstream activation of ERK, which may be necessary for the proper function of OAF, thus indirectly reducing its activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K. Similar to LY294002, by inhibiting PI3K, wortmannin can impede the Akt pathway and indirectly reduce the activity of OAF through decreased Akt-mediated cellular processes. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective inhibitor of Src family kinases. These kinases can phosphorylate a variety of substrates, including those that activate OAF. Inhibition of Src kinases by PP2 can prevent the activation of OAF that requires phosphorylation by these kinases. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Gö6983 is a broad-spectrum protein kinase C (PKC) inhibitor. By inhibiting various PKC isoforms, Gö6983 can reduce the phosphorylation and subsequent activation of OAF, as PKC is a kinase that potentially influences OAF's activity. | ||||||